Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)
Feb. 3, 2014 Kadimastem announces its intention to reduce the exercise price for warrants (Series 1) This change should benefit warrant...
Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)
Kadimastem Augments the Company's ALS Activities
Kadimastem has received approval from the OCS to promote cell therapy
Merck Serono and Kadimastem MOU on Drug Screening and Discovery for Neurodegenerative Diseases
Kadimastem successfully completes an IPO and raised $5.5 Million USD
Pharmaceutical Company Merck Serono signs an agreement: Use Kadimastem's platform for drug screening
Dr. Eli Opper, joined Kadimastem's team of Advisors
Kadimastem appointed Mr. Ofer Haviv as a director
The new Chief Scientist, Mr. Avi Hasson visits Kadimastem
The Chief Scientist visits Kadimastem